BioSpace News Archive

Researchers test CRISPR in blood disorders and extend CAR-T therapy to benefit more patients

Two analyses of the Phase 3 CLL14 study evaluated minimal residual disease (MRD) measurements for previously untreated CLL patients taking VENCLEXTA/VENCLYXTO in combination with obinutuzumab

Additional data, including EEG findings, support prior initial indications of activity and there were no new adverse events

Combined results from Phase 1b/2 CARTITUDE-1 study presented at ASH 2020 show 97 percent overall response rate at median follow-up of 12.4 months

Cellectis’ Proprietary Program UCART22 was Safely Administered in BALLI-01 Phase 1 Study with No Dose-Limiting Toxicity or Evidence of Graft-Vs-Host Disease

Interim analysis from the investigational ELARA study shows, 65% of patients with r/r follicular lymphoma evaluated for efficacy achieved a complete response and the overall response rate was 83%

Data presented in an oral presentation at the 62nd American Society of Hematology Annual Meeting

First Reported Allogeneic CAR T Data in Multiple Myeloma Highlights Initial Safety and Efficacy in Heavily Pretreated, Refractory Patients

New data from the double-blind, placebo-controlled, randomized phase of the Phase 2 CAPTIVATE study presented at ASH 2020 showed that 95 percent of patients with undetectable minimal residual disease randomized to discontinue active treatment after twelve cycles of treatment with IMBRUVICA® plus venetoclax were disease-free and alive, supporting a fixed duration treatment approach

First-reported results for the subcutaneous formulation and updated results for the intravenous formulation presented at ASH 2020